China Vaccine Summit 2011
May 25 - 27, 2011
Beijing , China
Why this event?
With 1.3 billion inhabitants and over 17 million newborns annually, China is the world largest vaccine consumer and manufacturer. The current vaccine market in China was valued in 2009 to be around $700 million with a annual growth rate expected to increase from around 15% now to 25% over the nex few years, thanks to recently announced government healthcare reforms that aims to bring wider insurance coverage to the population and the emergings of vaccine preventable health threats such as pandemic influenza.
Attracted by its huge potential, investors and biopharmaceuticals from home and abroad are piling into China to strive for market shares to secure long term growth.
However, China’s vaccine industry is still in its infancy considering its immature regulatory regime for vaccine industrialization and IPR protection, poor R&D and production engineering capabilities for vaccine development.
Bringing gather regulators, local and international vaccine manufacturers, biotechs, NGOs, technology providers and investors, the Vaccine China 2011 will be probing into the dynamics of China’s vaccine industry from various perspectives and discussing best business strategies in expanding and accessing China’s vaccine markets.
With 1.3 billion inhabitants and over 17 million newborns annually, China is the world largest vaccine consumer and manufacturer. The current vaccine market in China was valued in 2009 to be around $700 million with a annual growth rate expected to increase from around 15% now to 25% over the nex few years, thanks to recently announced government healthcare reforms that aims to bring wider insurance coverage to the population and the emergings of vaccine preventable health threats such as pandemic influenza.
Attracted by its huge potential, investors and biopharmaceuticals from home and abroad are piling into China to strive for market shares to secure long term growth.
However, China’s vaccine industry is still in its infancy considering its immature regulatory regime for vaccine industrialization and IPR protection, poor R&D and production engineering capabilities for vaccine development.
Bringing gather regulators, local and international vaccine manufacturers, biotechs, NGOs, technology providers and investors, the Vaccine China 2011 will be probing into the dynamics of China’s vaccine industry from various perspectives and discussing best business strategies in expanding and accessing China’s vaccine markets.
Related events
China Vaccine Summit May 25 - 27, 2011
